Loading clinical trials...

Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma

NCT00048022•Hoffmann-La Roche

View on ClinicalTrials.gov

Summary

The primary objective of the study is to evaluate the anti-inflammatory action and safety of Ro 27-2441 (study drug) in asthmatic patients currently taking inhaled corticosteroids. The research is being conducted at up to 40 clinical research sites in the US. Study participants will have a number of visits to a research site over a 4-month period.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Persistent asthma for more than 1 year
•Currently receiving treatment with a stable dose of inhaled corticosteroids for more than 3 months
•In good health as demonstrated by medical history and physical exam
•Negative urine pregnancy test
•Commitment to use two forms of effective contraception simultaneously throughout the study duration and for 1 month after discontinuing therapy

Exclusion Criteria

•Hospitalization for treatment of asthma and/or treatment with oral/injectable corticosteroids within 3 months before the start of the study
•Undergoing allergy shots unless on a stable maintenance dose for 3 months before the start of the study
•History of chronic pulmonary diseases other than asthma
•Treatment of conditions other than asthma with oral corticosteroids within 1 month of the start of the study
•Current tobacco usage
•Smoking history of greater than 10 pack-year history of cigarette smoking (number of packs smoked per day times the number of years smoked)
•History or evidence of drug or alcohol abuse
•Diagnosis or evidence of an infectious illness within one month of Visit 1
•Clinically significant diseases as assessed by the study doctor
•Participation in another clinical study with an experimental drug within one month of start of the study

Locations (60)

Huntington Beach, California, United States

Los Angeles, California, United States

Mission Viejo, California, United States

San Diego, California, United States

San Jose, California, United States

Walnut Creek, California, United States

Boulder, Colorado, United States

Denver, Colorado, United States

Key Dates

Start Date

October 25, 2002

Primary Completion Date

February 2, 2004

Completion Date

February 2, 2004

Last Updated

June 19, 2017

Conditions

Asthma

Interventions

Dual Integrin Antagonist

DRUG

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

NCT07486401

Asthma ExacerbationsBiomarkers / Blood+1 more

View study

RECRUITING

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

NCT02327897

Asthma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 19, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma

Inclusion Criteria

Exclusion Criteria

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

Relationship of Airway Microbiota, Endotype and Phenotype in Adult Asthma

To Assess the Management of Patients on Global Initiative of Asthma (GINA) Step 4 and 5 Treatment in Hong Kong

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma